-
Reagents
- Flow Cytometry Reagents
-
Western Blotting and Molecular Reagents
- Immunoassay Reagents
-
Single-Cell Multiomics Reagents
- BD OMICS-One™ WTA Next Assay
- BD Rhapsody™ Targeted mRNA Kits
- BD Rhapsody™ ATAC-Seq Assays
- BD Rhapsody™ TCR/BCR Next Multiomic Assays
- BD OMICS-One™ Protein Panels
- BD® AbSeq Assay
- BD® Single-Cell Multiplexing Kit
- BD OMICS-Guard™ CRYO Preservation Buffer
- BD OMICS-Guard™ Sample Preservation Buffer
- BD Rhapsody™ Accessory Kits
- Functional Assays
-
Microscopy and Imaging Reagents
-
Cell Preparation and Separation Reagents
-
Dehydrated Culture Media
-
BD Biosciences Training Program
- Flow Cytometry Basic Training
-
Product-Based Training
- BD Accuri™ C6 Plus Cell Analyzer
- BD FACSAria™ Cell Sorter Cell Sorter
- BD FACSCanto™ Cell Analyzer
- BD FACSDiscover™ A8 Cell Analyzer
- BD FACSDiscover™ S8 Cell Sorter
- BD FACSDuet™ Sample Preparation System
- BD FACSLyric™ Cell Analyzer
- BD FACSMelody™ Cell Sorter
- BD FACSymphony™ Cell Analyzer
- BD LSRFortessa™ Cell Analyzer
- Advanced Training
Old Browser
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current location site or be switched to your location?
Combining Single-cell RNA-seq and Proteomics
Monocyte-derived dendritic cell-based therapeutic vaccine platforms have been widely evaluated in clinical trials, yet conventional maturation protocols often yield cells with limited IL-12p70 secretion and suboptimal cytotoxic T-cell priming. Alpha-type-1-polarized dendritic cells (αDC1) offer an alternative approach, leveraging type 1 and type 2 interferon-based maturation to enhance IL-12p70 production and drive robust Th1 immunity. While these αDC1 cells appear uniform under traditional analysis, advanced single-cell techniques reveal hidden complexity that may explain variable vaccine effectiveness.
This webinar will share preliminary findings from work at the Mailliard Lab at the University of Pittsburgh School of Medicine using scRNA-seq on the BD Rhapsody™ System combined with the BD OMICS-One™ APC Protein Panel and BD® AbSeq Antibody-Oligos to profile 42 surface markers. These data uncover multiple functionally distinct αDC1 subpopulations, each secreting unique immunomodulatory cytokines and chemokines. These insights shed light on how dendritic cell subsets orchestrate immune responses and suggest mechanisms underlying individual differences in vaccine outcomes. Identifying protein markers that distinguish these subsets will enable isolation and deeper characterization of their therapeutic potential.
Key takeaways:
- How combined RNA and protein analysis enhances dendritic cell characterization
- Insights into specialized αDC1 subpopulations and their immunomodulatory roles
- Strategies for improving dendritic cell-based vaccine design and T-cell priming
Speaker
![]() | Ally DePuyt, PhD candidate Mailliard Lab, Department of Infectious Diseases and Microbiology University of Pittsburgh School of Public Health Ally DePuyt is a doctoral candidate in Robbie Mailliard’s lab in the Division of Infectious Diseases at the University of Pittsburgh School of Medicine. She received her bachelor’s degree in cellular neuroscience from Colgate University, where she studied the anti-inflammatory effects of antidepressant medications on microglia and astrocytes. She then completed a post-baccalaureate fellowship in Miles Herkenham’s lab at the National Institute of Mental Health where she evaluated the impact of chronic psychological stress on innate immune dynamics at the blood-brain barrier. Her current research focuses on the use of dendritic cells as immunotherapeutics to promote long-term control of HIV-1. |
Access the on-demand webinar
*Required fields
For Research Use Only. Not for use in diagnostic or therapeutic procedures.
